Citations

Clear

2416 citation(s) found for "Yu, Jason L".

The pharmacy residency program guide to Twitter
Webb, Andrew , Margetak, Danielle, Schramm, Garrett E. , Mordino, Jason

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 19, 2022 | Volume: 4 | Issue: 4 | Pages: 507-513

10.1002/jac5.1372 Get It

AbstractBackgroundTwitter has emerged as a powerful networking and educational tool within the health care community. The instantaneous and casual nature of Twitter allows for easy access to a near limitless pool of medical professionals and the opportunity to share intra‐ and interprofessional knowledge. Beyond individual development, Twitter has the potential to positively impact pharmacy residency programs in a multitude of ways.ObjectiveThis article serves as a practical guide for pharmacy residency programs to implement and maintain a successful Twitter account.RecommendationsAt the program level, a Twitter account creates an official voice and brand while simultaneously providing detail and perspective beyond what a residency website may offer. Additionally, it allows for dynamic ground‐level engagement with prospective residency candidates, current residents, and preceptors which is mutually beneficial to the program audience. In the age of virtual recruitment, successfully utilizing digital tools to meet candidates where they are is essential for attracting the right candidate for the program. Implementation of a successful social media strategy has potential barriers that include garnering buy‐in from departmental leadership, operationalizing a social media team, and maintaining engagement momentum.ConclusionPharmacy residency programs should consider starting an official Twitter account.
Cardiac Magnetic Resonance at 3.0 T in Patients With C282Y Homozygous Hereditary Hemochromatosis
Byrne, Danielle, Walsh, John P., Murphy, Ross T., McMorrow, Jason, Fagan, Andrew J., Poetrzyk, Aneta Kecler, Durand, Michael E., Norris, Suzanne, McKiernan, Susan, King, Gerard, Meaney, James F., Daly, Caroline, Byrne, Danielle, Walsh, John P., Murphy, Ross T., McMorrow, Jason, Fagan, Andrew J., Poetrzyk, Aneta Kecler, Durand, Michael E., Norris, Suzanne, McKiernan, Susan, King, Gerard, Meaney, James F., Daly, Caroline

Mayo Clinic

Journal of Thoracic Imaging | April 15, 2022 | Volume: 37 | Issue: 5 | Pages: 300-306

10.1097/rti.0000000000000645 | PMID 35426858 Get It

Background: Iron-overload cardiomyopathy initially manifests with diastolic dysfunction and can progress to dilated cardiomyopathy if untreated. Previous studies have shown that patients with primary and secondary hemochromatosis can have subclinical left ventricle dysfunction with abnormalities on strain imaging. This study aimed to evaluate the relationship between cardiac T2* values and myocardial-wall strain in patients with hereditary hemochromatosis (HH) at the time of diagnosis and after a course of venesection treatment. Materials and Methods: Baseline cardiac magnetic resonance (CMR) at 3 T was performed in 19 patients with newly diagnosed HH with elevated serum ferritin levels and repeated after a course of treatment with venesection. Quantitative T2* mapping and strain analysis were performed offline using dedicated relaxometry fitting and feature-tracking software. Results: The majority (84%) of patients had normal baseline myocardial T2* values (mean 19.3 ms, range 8.9 to 31.2 ms), which improved significantly after venesection (mean 24.1 ms, range 11 to 38.1 ms) (P=0.021). Mean global radial strain significantly improved from 25.0 (range: 15.6 to 32.9) to 28.3 (range: 19.8 to 35.8) (P=0.001) and mean global circumferential strain improved, decreasing from −15.7 (range: −11.1 to −19.2) to −17.1 (range: −13.0 to −20.1) (P=0.001). Conclusion: Patients with HH may have normal T2* values in the presence of subclinical left ventricle dysfunction, which can be detected by abnormal radial and circumferential strain. As strain imaging improves following venesection in HH, it may serve as a useful biomarker to guide treatment.
Risk of Early Versus Later Rebleeding From Dural Arteriovenous Fistulas With Cortical Venous Drainage
Durnford, Andrew , Akarca, Danyal , Culliford, David , Millar, John S. , Guniganti, Ridhima , Giordan, Enrico , Brinjikji, Waleed , Chen, Ching‐Jen , Abecassis, Isaac Josh , Levitt, Michael R. , Polifka, Adam , Derdeyn, Colin P. , Kwasnicki, Amanda , Alaraj, Ali , Potgieser, Adriaan R. E., Tada, Yoshiteru , Abla, Adib A. , Satomi, Junichiro, Starke, Robert M., Dijk, J. Marc C. van , Amin‐Hanjani, Sepideh , Hayakawa, M. , Gross, Bradley A. , Kim, Louis J. , Sheehan, Jason P. , Kansagra, Akash P. , Lai, Rosalind, Zipfel, Gregory J. , Bulters, Diederik , Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J. , Patibandla, Mohana Rao, Ding, Dale , Buell, Thomas J. , Paisan, Gabriella, Meyer, R. Michael, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Macdonald, Jason, Laurent, Dimitri , Lockerman, Ashley, Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Sur, Samir , Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Winkler, Ethan A. , Lawton, Michael T. , Rutkowski, Martin J. , Sultan, M. Ali Aziz, Patel, Nirav , Frerichs, Kai U., Levitt, Michael R , Polifka, Adam J , Samaniego, Edgar A , Alaraj, Ali , Tada, Yoshiteru , Phelps, Ryan , Abla, Adib , van DijK, J Marc C , Amin-Hanjani, Sepideh , Gross, Bradley , Fox, W Christopher , Kim, Louis J. , Sheehan, Jason , Lanzino, Giuseppe , Kansagra, Akash P , Du, Rose , Lai, Rosalind , Zipfel, Gregory J , Bulters, Diederik O , Ding, Dale , Chen, Ching-Jen , Derdeyn, Colin P , Abecassis, Isaac Josh , Millar, John, Chen, Stephanie , Lanzino, Giuseppe , Raman, Hari S. , Lipsey, Kim L. , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki

Mayo Clinic

Stroke | April 14, 2022 | Volume: 53 | Issue: 7 | Pages: 2340-2345

10.1161/strokeaha.121.036450 | PMID 35420453 Get It

Background: Cranial dural arteriovenous fistulas with cortical venous drainage are rare lesions that can present with hemorrhage. A high rate of rebleeding in the early period following hemorrhage has been reported, but published long-term rates are much lower. No study has examined how risk of rebleeding changes over time. Our objective was to quantify the relative incidence of rebleeding in the early and later periods following hemorrhage. Methods: Patients with dural arteriovenous fistula and cortical venous drainage presenting with hemorrhage were identified from the multinational CONDOR (Consortium for Dural Fistula Outcomes Research) database. Natural history follow-up was defined as time from hemorrhage to first treatment, rebleed, or last follow-up. Rebleeding in the first 2 weeks and first year were compared using incidence rate ratio and difference. Results: Of 1077 patients, 250 met the inclusion criteria and had 95 cumulative person-years natural history follow-up. The overall annualized rebleed rate was 7.3% (95% CI, 3.2–14.5). The incidence rate of rebleeding in the first 2 weeks was 0.0011 per person-day; an early rebleed risk of 1.6% in the first 14 days (95% CI, 0.3–5.1). For the remainder of the first year, the incidence rate was 0.00015 per person-day; a rebleed rate of 5.3% (CI, 1.7–12.4) over 1 year. The incidence rate ratio was 7.3 (95% CI, 1.4–37.7; P , 0.026). Conclusions: The risk of rebleeding of a dural arteriovenous fistula with cortical venous drainage presenting with hemorrhage is increased in the first 2 weeks justifying early treatment. However, the magnitude of this increase may be considerably lower than previously thought. Treatment within 5 days was associated with a low rate of rebleeding and appears an appropriate timeframe.
Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice
Evgin, Laura , Kottke, Tim , Tonne, Jason M., Thompson, Jill , Huff, Amanda L. , Vloten, Jacob P. van , Moore, Madelyn , Michael, Josefine, Driscoll, Christopher B. , Pulido, José S. , Swanson, Eric , Kennedy, Richard B. , Loghmani, Houra , Sánchez-Pérez, Luis, Olivier, Gloria , Harrington, Kevin J. , Pandha, Hardev , Melcher, Alan , Díaz, Rosa María, Vile, Richard G. , Tonne, Jason , van Vloten, Jacob , Driscoll, Christopher , Pulido, Jose, Kennedy, Richard , Coffey, Matt C. , Olivier, Gloria , Harrington, Kevin , Melcher, Alan A , Swanson, Eric

Mayo Clinic

Science Translational Medicine | April 13, 2022 | Volume: 14 | Issue: 640 | Pages: No page available

10.1126/scitranslmed.abn2231 | PMID 35417192 Get It

Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells in the solid tumor microenvironment (TME). Here, using systemically delivered OVs and CAR T cells in immunocompetent mouse models, we have defined a mechanism by which OVs can potentiate CAR T cell efficacy against solid tumor models of melanoma and glioma. We show that stimulation of the native T cell receptor (TCR) with viral or virally encoded epitopes gives rise to enhanced proliferation, CAR-directed antitumor function, and distinct memory phenotypes. In vivo expansion of dual-specific (DS) CAR T cells was leveraged by in vitro preloading with oncolytic vesicular stomatitis virus (VSV) or reovirus, allowing for a further in vivo expansion and reactivation of T cells by homologous boosting. This treatment led to prolonged survival of mice with subcutaneous melanoma and intracranial glioma tumors. Human CD19 CAR T cells could also be expanded in vitro with TCR reactivity against viral or virally encoded antigens and was associated with greater CAR-directed cytokine production. Our data highlight the utility of combining OV and CAR T cell therapy and show that stimulation of the native TCR can be exploited to enhance CAR T cell activity and efficacy in mice.
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Adashek, Jacob J. , Menta, Arjun K. , Reddy, Neha K. , Desai, Aakash , Roszik, Jason , Subbiah, Vivek , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Molecular Cancer Therapeutics | April 12, 2022 | Volume: 21 | Issue: 6 | Pages: 871-878

10.1158/1535-7163.mct-21-0950 | PMID 35413124 Get It

Abstract BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600–mutated colorectal cancer has prevented its tissue-agnostic drug development. We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We reviewed the literature for case reports of clinical responses, outcomes in patients with BRAF V600 mutation—positive nonmelanoma malignancies who received BRAF inhibitor therapy, and data from published adult and pediatric trials. BRAF V600 mutations are prevalent across multiple nonmelanoma malignancies (>40 different tumor types), lead to oncogene addiction, and are clinically actionable in a broad range of adult and pediatric nonmelanoma rare malignancies. Continued tissue-agnostic drug development is warranted beyond the current BRAF plus MEK approved cancers.
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective
Aggarwal, Neelum T. , Vila‐Castelar, Clara , Brugulat‐Serrat, Anna , Foldi, Nancy S. , Gilsanz, Paola , Li, Wei , McManus, Alison J. , Lent, Debora Melo van , Milani, Sadaf Arefi , Shaaban, C. Elizabeth , Stites, Shana D. , Trani, Jean‐Francoise, Turner, Arlener D. , Vonk, Jet M. J. , Quiroz, Yakeel T. , Group, for the Diversity and Disparity Professional Interest Area Sex and Gender Special Interest, Mielke, Michelle M. , Agarwal, Puja , Arenaza‐Urquijo, Eider M. , Brett, Benjamin L. , DuBose, Lyndsey Elisabeth , Eikelboom, Willem S. , Flatt, Jason D. , Franzen, Sanne , Sundermann, Erin E. , Suryadevara, Vidyani , Babulal, Ganesh M. , Group, for the Diversity and Disparity Professional Interest Area Sex and Gender Special Interest

Mayo Clinic

Alzheimer's & Dementia | April 8, 2022 | Volume: 18 | Issue: 12 | Pages: 2707-2724

10.1002/alz.12662 | PMID 35394117 Get It

Abstract Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD) differ by world region, suggesting that there are potentially modifiable risk factors for intervention. However, few epidemiological or clinical ADRD studies examine sex differences; even fewer evaluate gender in the context of ADRD risk. The goals of this perspective are to: (1) provide definitions of gender, biologic sex, and sexual orientation. and the limitations of examining these as binary variables; (2) provide an overview of what is known with regard to sex and gender differences in the risk, prevention, and diagnosis of ADRD; and (3) discuss these sex and gender differences from a global, worldwide perspective. Identifying drivers of sex and gender differences in ADRD throughout the world is a first step in developing interventions unique to each geographical and sociocultural area to reduce these inequities and to ultimately reduce global ADRD risk. Highlights The burden of dementia is unevenly distributed geographically and by sex and gender. Scientific advances in genetics and biomarkers challenge beliefs that sex is binary. Discrimination against women and sex and gender minority (SGM) populations contributes to cognitive decline. Sociocultural factors lead to gender inequities in Alzheimer's disease and related dementias (ADRD) worldwide.
Stereotactic Radiosurgery for Dural Arteriovenous Fistulas: A Systematic Review and Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines
Singh, Raj , Didwania, Prabhanjan, Kotecha, Rupesh , Pollock, Bruce E. , Yomo, Shoji , Sahgal, Arjun , Sheehan, Jason P. , Chen, Ching‐Jen , Fariselli, Laura , Levivier, Marc , Paddick, Ian , Suh, John H.

Mayo Clinic

Neurosurgery | April 5, 2022 | Volume: 91 | Issue: 1 | Pages: 43-58

10.1227/neu.0000000000001953 | PMID 35383682 Get It

BACKGROUND: Dural arteriovenous fistulas (dAVFs) are often treated with stereotactic radiosurgery (SRS) to achieve complete obliteration (CO), prevent future hemorrhages, and ameliorate neurological symptoms. OBJECTIVE: To summarize outcomes after SRS for dAVFs and propose relevant practice recommendations. METHODS: Using a PICOS/PRISMA/MOOSE protocol, we included patients with dAVFs treated with SRS and data for at least one of the outcomes of the study. Relevant outcomes were CO, symptom improvement and cure, and post-SRS hemorrhage or permanent neurological deficits (PNDs). Estimated outcome effect sizes were determined using weighted random-effects meta-analyses using DerSimonian and Laird methods. To assess potential relationships between patient and lesion characteristics and clinical outcomes, mixed-effects weighted regression models were used. RESULTS: Across 21 published studies, we identified 705 patients with 721 dAVFs treated with SRS. The CO rate was 68.6% (95% CI 60.7%-76.5%) with symptom improvement and cure rates of 97.2% (95% CI 93.2%-100%) and 78.8% (95% CI 69.3%-88.2%), respectively. Estimated incidences of post-SRS hemorrhage and PNDs were 1.1% (95% CI 0.6%-1.6%) and 1.3% (95% CI 0.8%-1.8%), respectively. Noncavernous sinus (NCS) dAVFs were associated with lower CO ( P = .03) and symptom cure rates ( P = .001). Higher grade was also associated with lower symptom cure rates ( P = .04), whereas previous embolization was associated with higher symptom cure rates ( P = .01). CONCLUSION: SRS for dAVFs results in CO in the majority of patients with excellent symptom improvement rates with minimal toxicity. Patients with NCS and/or higher-grade dAVFs have poorer symptom cure rates. Combined therapy with embolization and SRS is recommended when feasible for clinically aggressive dAVFs or those refractory to embolization to maximize the likelihood of symptom cure.
The incidence of lumbar spine surgery following Minimally Invasive Lumbar Decompression and Superion Indirect Decompression System for treatment of lumbar spinal stenosis: a retrospective review
Hagedorn, Jonathan M. , Yadav, Abhishek , D’Souza, Ryan S. , DeTemple, Nathan, Wolff, Jason S., Parmele, James B., Hagedorn, Jonathan M , D'Souza, Ryan S , Deer, Timothy R.

Mayo Clinic

Pain Practice | April 4, 2022 | Volume: 22 | Issue: 5 | Pages: 516-521

10.1111/papr.13111 | PMID 35373492 Get It

Abstract Introduction Lumbar spinal stenosis affects more than 200,000 adults in the United States, resulting in approximately 38,000 operations among the Medicare population and greater than $1.5 billion in hospital bills alone. Fortunately, Minimally Invasive Lumbar Decompression (MILD) and the Superion Indirect Decompression System have shown lasting benefit and cost savings compared to more aggressive surgical options. Objective Our primary objective was to retrospectively determine the rate of lumbar decompression surgery following the MILD and Superion procedures. Materials and Methods This was a pooled retrospective review of LSS patients who received MILD and/or Superion procedures between January 2011 and July 2019. Adult patients with CPT codes for MILD and Superion procedures were identified. Patients were included if they had a follow‐up visit at least 2 years from the procedure date, preprocedural MRI results, and surgical notes. Results A total of 199 patients were included in the final analysis, of which 57 patients (28.6%) underwent MILD procedure only, 124 patients (62.3%) underwent Superion only, and 18 patients (9.0%) underwent an MILD procedure initially followed by a Superion procedure. Two patients had an MILD procedure performed twice at the same level at separate encounters. A total of four patients in the entire cohort (2.0%; MILD 5.3%, Superion 0.8%) underwent subsequent lumbar spine surgery when followed for at least 2 years. It is notable that some of these patients may not have been surgical candidates and this may have skewed the results. Conclusions Patients undergoing minimally invasive decompression treatment of lumbar spinal stenosis have low rates of subsequent open surgery which potentially results in cost savings and a reduction in severe adverse events. The reason for low surgical rate may reflect improvement in their symptoms, a preference to avoid surgery, or being deemed not a surgical candidate.
P98. HOME SWEET HOME: THE INTEGRATED PLASTIC SURGERY RESIDENCY MATCH DURING THE COVID-19 PANDEMIC
Antezana, Luis A. , Muro-Cardenas, Jose , Xie, Katherine , Weissler, Jason M., Bakri, Karim , Antezana, Luis , Rode, Matthew M. , Bakri, Karim

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 96-96

10.1097/01.gox.0000828740.31707.12 Get It

35. BROWLIFT: CORRELATION OF ARTIFICIAL INTELLIGENCE WITH EXCURSION MEASUREMENTS IN IDENTIFYING SURGICAL EFFICACY
Boonipat, Thanapoom , Hebel, Nathan , Callori, Steven , Lin, Jason , Bite, Uldis

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 18-18

10.1097/01.gox.0000828128.08724.ed Get It